Meridian Bioscience Inc. (VIVO)
(Delayed Data from NSDQ)
$11.51 USD
-0.48 (-4.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.51 USD
-0.48 (-4.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost
by Zacks Equity Research
Becton, Dickinson (BDX) receives a number of regulatory approvals of late.
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) makes a few lucrative acquisitions in recent times.
Medical Products Industry Outlook: Plenty of Upside Left
by Zacks Equity Research
The growing adoption of AI, Medical Mechatronics & Robotics has lent the Medical Products industry a competitive edge in the broader medical market.
Meridian Bioscience (VIVO) Tops Q1 Earnings Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 11.11% and -0.04%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Ericsson (ERIC) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ericsson (ERIC) is likely to report higher year-over-year revenues in the fourth quarter of 2018 on the back of healthy growth dynamics.
New Strong Buy Stocks for January 21st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Meridian Bioscience (VIVO) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 25.00% and 3.74%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience (VIVO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience (VIVO) Q3 Earnings Beat Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 5.88% and -0.42%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
MedTech Growing on Emerging Markets, M&A: Stocks to Buy
by Zacks Equity Research
Given the current lack of clarity, let???s concentrate on some powerful long-term tailwinds of the medical device industry like emerging market expansion, mergers & acquisitions (M&A), positive demographic trends and new product innovation.
Meridian (VIVO) Initiates illumigene CMV Trial, Shares Shine
by Zacks Equity Research
Solid share price rally following the news suggests that the latest development is likely to buoy Meridian's (VIVO) bottom line and enhance its illumigene platform.
MedTech Industry Outlook - July 2017
by Zacks Equity Research
The overall expectation is that President Trump's legislative change for MedTech will result in lower taxes and regulation for the industry as a whole.
Top Ranked Income Stocks to Buy for May 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 24th:
Top Ranked Momentum Stocks to Buy for May 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 22nd:
Top Ranked Income Stocks to Buy for May 18th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 18th:
Top Ranked Income Stocks to Buy for May 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 12th:
Meridian (VIVO) to Provide LeadCare Testing System in Africa
by Zacks Equity Research
Meridian Bioscience, Inc. (VIVO), a renowned life sciences company, recently signed an exclusive distribution agreement with Biofirm Technologies.
What Makes Meridian Bioscience (VIVO) a Strong Sell?
by Zacks Equity Research
Meridian Bioscience (VIVO), has witnessed a significant price decline and negative trend in earnings estimate revisions
Meridian Bioscience Partners MedCaptain, Expands in China
by Zacks Equity Research
Meridian Bioscience, Inc. (VIVO) announced that its Magellan Diagnostics business has signed a distribution agreement with China-based MedCaptain Medical Technology.